Source: Diabetology and Metabolic Syndrome. Unidade: FM
Subjects: BIOMARCADORES, INFLAMAÇÃO, FÁRMACOS IMUNOSSUPRESSORES, METABOLISMO, DIABETES MELLITUS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TOSTES, Glauce Cordeiro Ulhôa et al. Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study. Diabetology and Metabolic Syndrome, v. 8, p. 9 , 2016Tradução . . Disponível em: http://dmsjournal.biomedcentral.com/articles/10.1186/s13098-015-0120-6. Acesso em: 14 nov. 2024.APA
Tostes, G. C. U., Cunha, M. R., Fukui, R. T., Correia, M. R. S., Rocha, D. M., Santos, R. F. dos, & Silva, M. E. R. da. (2016). Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study. Diabetology and Metabolic Syndrome, 8, 9 . doi:10.1186/s13098-015-0120-6NLM
Tostes GCU, Cunha MR, Fukui RT, Correia MRS, Rocha DM, Santos RF dos, Silva MER da. Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study [Internet]. Diabetology and Metabolic Syndrome. 2016 ; 8 9 .[citado 2024 nov. 14 ] Available from: http://dmsjournal.biomedcentral.com/articles/10.1186/s13098-015-0120-6Vancouver
Tostes GCU, Cunha MR, Fukui RT, Correia MRS, Rocha DM, Santos RF dos, Silva MER da. Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study [Internet]. Diabetology and Metabolic Syndrome. 2016 ; 8 9 .[citado 2024 nov. 14 ] Available from: http://dmsjournal.biomedcentral.com/articles/10.1186/s13098-015-0120-6
